Cost of care distribution in atrial fibrillation patients: the COCAF study

Heuzey, J.-Y. Le; Paziaud, Olivier; Piot, Olivier

doi:10.1016/j.accreview.2004.03.017

Cited by 61 publications

(83 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,9 Not surprisingly, the costs of managing AF are substantial, with annual costs estimated at $4700 per patient 10 or $6.65 billion across the United States, 11 largely driven by inpatient hospital admissions. 11,12 Although effective treatments are available to maintain and restore sinus rhythm in AF/AFL patients, 13 these have had little impact on hospitalization rates, which have tended to rise year-on-year. 4,14,15 Recently, the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone, a novel antiarrhythmic therapy, significantly reduced the risk of hospitalization for CV causes or inpatient death from any cause in patients with AF/AFL.…”

Section: Introductionmentioning

confidence: 99%

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Naccarelli

Johnston

Lin

et al. 2010

Clinical Cardiology

View full text Add to dashboard Cite

Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and inpatient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients.Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. The most common nonfatal causes of CV hospitalizationswere AF/other supraventricular rhythm disorders (20.2% of all CV hospitalizations),congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%). Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264 (2.6%) patients; the most common causes of CV inpatient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%). Mean hospitalizationcosts per CV inpatient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Naccarelli

Johnston

Lin

et al. 2010

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…4) AF currently represents a major economic burden for society in light of the aging population. [5][6][7] The Maze procedure provides excellent results for surgical treatment of AF. 8) This surgical approach was designed to block multiple macroreentrant circuits that were the putative cause of AF.…”

Section: Introductionmentioning

confidence: 99%

Impact of Medical Treatment on Long-Term Results after Surgical Ablation of Atrial Fibrillation in Cardiac Surgical Patients

Feyrer¹,

Ballazhi²,

Seitz³

et al. 2014

ATCS

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the long-term outcome (4 years) of high-intensity-focused-ultrasound (HIFU) cardiac ablation, the significance of postablation antiarrhythmic drugs (AADs) and predictors of successful sinus rhythm (SR) restoration. Methods: 103 patients were prospectively enrolled in a single-center study. The preoperative atrial fibrillation (AF) type was paroxysmal in 36%, permanent in 53%, persistent in 5% and flutter in 6% patients. The left atrial diameter was <50 mm in 78 patients and >50 mm in 25. Long-term results, up to 4 years, and postablation antiarrhythmics were evaluated.

show abstract

“…За последние 20 лет частота госпитализаций по поводу ФП возрос-ла на 66% [7] в результате старения населения, уве-личения распространенности хронических заболеваний сердца, более частой диагностики при амбулаторном мониторировании ЭКГ и других факторов. ФП являет-ся причиной значительных затрат для здравоохранения (примерно 3000 евро или 3600 долларов на больно-го в год) [8]; в Европейском союзе общие затраты, свя-занные с ФП, достигают 13,5 млрд евро (или 15,7 млрд долларов).…”

Section: эпидемиология и прогнозunclassified

American College of Cardiology, American Heart Association and European Society of Cardiology (2006) Guidelines for the Management of Patients With Atrial Fibrillation

Fuster¹,

Ryden²,

Cannom³

et al. 2007

Racionalʹnaâ farmakoterapiâ v kardiologii

Self Cite

120

View full text Add to dashboard Cite

Отчет рабочей группы Американской коллегии кардиологов и Американской ассоциации сердца по практическим рекомендациям и комитета Европейского общества кардиологов по практическим рекомендациям Рекомендации разработаны в сотрудничестве с Европейской ассоциацией сердечного ритма и Обществом сердечного ритма Авторы (члены рабочей группы): V.

show abstract

Cost of care distribution in atrial fibrillation patients: the COCAF study

Cited by 61 publications

References 0 publications

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Impact of Medical Treatment on Long-Term Results after Surgical Ablation of Atrial Fibrillation in Cardiac Surgical Patients

American College of Cardiology, American Heart Association and European Society of Cardiology (2006) Guidelines for the Management of Patients With Atrial Fibrillation

Contact Info

Product

Resources

About